These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 33999422)

  • 21. FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer.
    Narayan P; Osgood CL; Singh H; Chiu HJ; Ricks TK; Chiu Yuen Chow E; Qiu J; Song P; Yu J; Namuswe F; Guiterrez-Lugo M; Hou S; Pierce WF; Goldberg KB; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
    Clin Cancer Res; 2021 Aug; 27(16):4478-4485. PubMed ID: 33753456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
    Takahashi S; Karayama M; Takahashi M; Watanabe J; Minami H; Yamamoto N; Kinoshita I; Lin CC; Im YH; Achiwa I; Kamiyama E; Okuda Y; Lee C; Bang YJ
    Clin Cancer Res; 2021 Nov; 27(21):5771-5780. PubMed ID: 34426442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan.
    Ali A; Graff SL
    Curr Oncol Rep; 2024 Jan; 26(1):1-9. PubMed ID: 38091201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
    Shitara K; Baba E; Fujitani K; Oki E; Fujii S; Yamaguchi K
    Gastric Cancer; 2021 Jul; 24(4):780-789. PubMed ID: 33997928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
    Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
    Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
    Dowling GP; Toomey S; Bredin P; Parker I; Mulroe E; Marron J; McLoughlin O; Teiserskiene A; Power C; O'Shea AM; Greally M; Morris PG; Duke D; Hill ADK; Hennessy BT
    BMC Cancer; 2024 Jan; 24(1):91. PubMed ID: 38233810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.
    Nakajima H; Harano K; Nakai T; Kusuhara S; Nakao T; Funasaka C; Kondoh C; Matsubara N; Naito Y; Hosono A; Mitsunaga S; Ishii G; Mukohara T
    Breast; 2022 Feb; 61():136-144. PubMed ID: 34999427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
    Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
    Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
    Nakajima S; Mimura K; Matsumoto T; Thar Min AK; Ito M; Nakano H; Neupane P; Kanke Y; Okayama H; Saito M; Momma T; Watanabe Y; Hanayama H; Hayase S; Saze Z; Kono K
    Sci Rep; 2021 Aug; 11(1):16891. PubMed ID: 34413454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
    Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im SA; Nowecki Z; Sohn J; Laurentiis M; Jañez NM; Adamo B; Lee KS; Jung KH; Rubovszky G; Tseng LM; Lu YS; Yuan Y; Maxwell MJ; Haddad V; Khan SS; Rugo HS; Pistilli B
    Future Oncol; 2024 Mar; 20(8):423-436. PubMed ID: 37387213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.
    Jerusalem G; Park YH; Yamashita T; Hurvitz SA; Modi S; Andre F; Krop IE; Gonzàlez Farré X; You B; Saura C; Kim SB; Osborne CR; Murthy RK; Gianni L; Takano T; Liu Y; Cathcart J; Lee C; Perrin C
    Cancer Discov; 2022 Dec; 12(12):2754-2762. PubMed ID: 36255231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
    N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2-Positive or HER2-Low Metastatic/Unresectable Breast Cancer.
    Shimomura A; Takano T; Takahashi S; Sagara Y; Watanabe J; Tokunaga E; Shinkai T; Kamio T; Kikumori K; Kamiyama E; Fujisaki Y; Saotome D; Yamashita T
    Clin Pharmacol Ther; 2023 Jan; 113(1):160-169. PubMed ID: 36164935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
    Bardia A; Krop IE; Kogawa T; Juric D; Tolcher AW; Hamilton EP; Mukohara T; Lisberg A; Shimizu T; Spira AI; Tsurutani J; Damodaran S; Papadopoulos KP; Greenberg J; Kobayashi F; Zebger-Gong H; Wong R; Kawasaki Y; Nakamura T; Meric-Bernstam F
    J Clin Oncol; 2024 Jul; 42(19):2281-2294. PubMed ID: 38652877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.
    Ciruelos E; García-Sáenz JÁ; Gavilá J; Martín M; Rodríguez CA; Rodríguez-Lescure Á
    Clin Transl Oncol; 2024 Jul; 26(7):1539-1548. PubMed ID: 38336982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice.
    Okamoto H; Oitate M; Hagihara K; Shiozawa H; Furuta Y; Ogitani Y; Kuga H
    Xenobiotica; 2020 Oct; 50(10):1242-1250. PubMed ID: 32306807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
    Ishii T; Shitara K
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1193-1201. PubMed ID: 34543577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study.
    Botticelli A; Caputo R; Scagnoli S; Pisegna S; De Laurentiis M; Curigliano G; Lambertini M; Pantano F; Palazzo A; Paris I; Vernieri C; Tedesco B; Giampaglia M; Palleschi M; Ballatore Z; Alesini D; D'Auria G; Fabbri A; Rossi L; Verrazzo A; Scafetta R; Marinelli D; Sposetti C; Barberi V; Strigari L; Marchetti P; Santini D; Fabi A
    Oncologist; 2024 Apr; 29(4):303-310. PubMed ID: 37995313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.